Which AI agents work with Es Non Reconstituted Vs Reconstituted Glucagon Severe Hypo?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Who published Es Non Reconstituted Vs Reconstituted Glucagon Severe Hypo?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Es Non Reconstituted Vs Reconstituted Glucagon Severe Hypo by dromlakhani

Name: Es Non Reconstituted Vs Reconstituted Glucagon Severe Hypo
Rating: 4.666666666666667 (3 reviews)
Author: dromlakhani

Es Non Reconstituted Vs Reconstituted Glucagon Severe Hypo

Recommends non-reconstituted glucagon preparations over reconstituted ones for treating outpatients with severe hypoglycemia. Triggered by questions such as "Should I use non-reconstituted or reconstituted glucagon for this patient with severe hypoglycemia?" or "Is ready-to-use glucagon preferred for emergency treatment?"

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

Non-Reconstituted vs Reconstituted Glucagon for Severe Hypoglycemia

STEP 1 — Gather Information

Confirm outpatient setting and presence of Level 3 hypoglycemia (altered mental/physical status requiring assistance). Verify no contraindications (e.g., known glucagon allergy, pheochromocytoma, insulinoma). Assess caregiver ability to administer glucagon and availability of specific products (nasal, autoinjector, prefilled syringe).

STEP 2 — Rule In / Rule Out

If hypoglycemia is Level 1 or 2 (symptomatic but able to self-treat), rule out glucagon and administer oral carbohydrates. If Level 3 (severe, requiring assistance), rule in glucagon therapy and proceed to product selection.

STEP 3 — Classify or Stratify

Prefer non-reconstituted glucagon (ready-to-use) over reconstituted glucagon (powder + diluent) based on evidence of easier administration and reduced dosing errors. If non-reconstituted formulation is unavailable or contraindicated, consider reconstituted glucagon with ensured caregiver training.

STEP 4 — Decide

Administer non-reconstituted glucagon: nasal glucagon (Baqsimi) for ages ≥4, dasiglucagon (Gvoke) autoinjector/prefilled syringe for ages ≥6, or stable liquid glucagon (Zegalogue) for ages ≥2. If only reconstituted glucagon kit is available, reconstitute per instructions and administer IM/SC, ensuring caregiver competence.

Clinical Guardrails / Mimics / Pitfalls

Do not delay glucagon administration while attempting oral carbohydrates in Level 3 hypoglycemia. Avoid glucagon in patients with pheochromocytoma or insulinoma due to risk of hypertension or hypoglycemia exacerbation. Do not rely on reconstituted glucagon if caregiver cannot reliably reconstitute under stress; training and product familiarity are critical. Monitor for nausea/vomiting post-administration.

Concrete Clinical Example

A 14-year-old with type 1 diabetes is found confused and diaphoretic with point-of-care glucose 28 mg/dL; sibling administers Baqsimi nasal glucagon (one spray in nostril), patient regains consciousness and oral intake within 4 minutes.

Source: Management of Individuals With Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, https://doi.org/10.1210/clinem/dgac596

---name: es-non-reconstituted-vs-reconstituted-glucagon-severe-hypodescription: Recommends non-reconstituted glucagon preparations over reconstituted ones for treating outpatients with severe hypoglycemia. Triggered by questions such as "Should I use non-reconstituted or reconstituted glucagon for this patient with severe hypoglycemia?" or "Is ready-to-use glucagon preferred for emergency treatment?"---# Non-Reconstituted vs Reconstituted Glucagon for Severe Hypoglycemia## STEP 1 — Gather InformationConfirm outpatient setting and presence of Level 3 hypoglycemia (altered mental/physical status requiring assistance). Verify no contraindications (e.g., known glucagon allergy, pheochromocytoma, insulinoma). Assess caregiver ability to administer glucagon and availability of specific products (nasal, autoinjector, prefilled syringe).## STEP 2 — Rule In / Rule OutIf hypoglycemia is Level 1 or 2 (symptomatic but able to self-treat), rule out glucagon and administer oral carbohydrates. If Level 3 (severe, requiring assistance), rule in glucagon therapy and proceed to product selection.## STEP 3 — Classify or StratifyPrefer non-reconstituted glucagon (ready-to-use) over reconstituted glucagon (powder + diluent) based on evidence of easier administration and reduced dosing errors. If non-reconstituted formulation is unavailable or contraindicated, consider reconstituted glucagon with ensured caregiver training.## STEP 4 — DecideAdminister non-reconstituted glucagon: nasal glucagon (Baqsimi) for ages ≥4, dasiglucagon (Gvoke) autoinjector/prefilled syringe for ages ≥6, or stable liquid glucagon (Zegalogue) for ages ≥2. If only reconstituted glucagon kit is available, reconstitute per instructions and administer IM/SC, ensuring caregiver competence.## Clinical Guardrails / Mimics / PitfallsDo not delay glucagon administration while attempting oral carbohydrates in Level 3 hypoglycemia. Avoid glucagon in patients with pheochromocytoma or insulinoma due to risk of hypertension or hypoglycemia exacerbation. Do not rely on reconstituted glucagon if caregiver cannot reliably reconstitute under stress; training and product familiarity are critical. Monitor for nausea/vomiting post-administration.## Concrete Clinical ExampleA 14-year-old with type 1 diabetes is found confused and diaphoretic with point-of-care glucose 28 mg/dL; sibling administers Baqsimi nasal glucagon (one spray in nostril), patient regains consciousness and oral intake within 4 minutes.**Source:** Management of Individuals With Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, https://doi.org/10.1210/clinem/dgac596

Frequently asked questions